Loreto Fernández-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loreto Fernández-González has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Paulina Bravo
Instituto Oncológico Fundación Arturo López Pérez, Providencia, Chile
5 shared publications - Angelina Dois
Pontificia Universidad Católica de Chile
4 shared publications - Alejandra Martinez-Pereira
Center for Technology and Behavioral Health, Lebanon, NH, USA
3 shared publications - Luis Villarroel
Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile , Santiago
3 shared publications - Anne-Emanuelle Birn
University of Toronto
2 shared publications - Constanza Quezada
Affiliations School of Nursing, Faculty of Medicine, Pontifical Catholic University of Chile, Santiago de Chile, Chile, Faculty of Social, Legal and Humanities Sciences, Gabriela Mistral University, Santiago de Chile, Chile
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
Validation of the Spanish version of the shame and sigma scale for head and neck cancer survivors
Validation of the Spanish version of the shame and sigma scale for head and neck cancer survivors Loreto Fernández-González1a, Rodrigo Lagos2b, Piero Betto
- 3 November 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
Open AccessValidation of the Spanish version of the shame and sigma scale for head and neck cancer survivors
Validation of the Spanish version of the shame and sigma scale for head and neck cancer survivors Loreto Fernández-González1a, Rodrigo Lagos2b, Piero Betto
- Open Access
- 19 June 2026
- Published by Elsevier in SSM - Qualitative Research in Health
- Vol. 10
Seizing the opportunity: accessing the unaffordable standard of care in commercial clinical trials for advanced cancer in Chile
- 19 June 2026
- Published by Elsevier in SSM - Qualitative Research in Health
- Vol. 10
Open AccessSeizing the opportunity: accessing the unaffordable standard of care in commercial clinical trials for advanced cancer in Chile
- Open Access
- 28 November 2025
- Published by Springer Nature in Globalization and Health
- Vol. 21 (1) , 69
“If I am here, it is because the system failed”: a critical qualitative study of global commercial clinical trials for advanced cancer in Chile
The pharmaceutical industry is a key global health actor given its crucial role in the development and testing of medicines. Within Latin America, Chile cu
- 28 November 2025
- Published by Springer Nature in Globalization and Health
- Vol. 21 (1) , 69
Open Access“If I am here, it is because the system failed”: a critical qualitative study of global commercial clinical trials for advanced cancer in Chile
The pharmaceutical industry is a key global health actor given its crucial role in the development and testing of medicines. Within Latin America, Chile cu
- 28 March 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (4) , e70138
What Decisions Matter to Women Facing a Breast Cancer Diagnosis? A Case Study From the Global South on Treatment Shared Decision‐Making and the Management of Distress
Background: Breast cancer (BC) is the leading cause of cancer deaths among Chilean women. BC treatment is guaranteed by Chilean law through the Explicit Health Guarantees (GES) plan. There is insufficient evidence on how women navigate the healthcare system and how they exercise shared decision‐making (SDM) following a BC diagnosis in global South scenarios. Aim: To understand how women make decisions about BC treatment. Methods: A qualitative study based on 29 individual, semi‐structured, in‐depth interviews with women undergoing BC treatment in three hospitals in Santiago. Recruitment took place from November 2022 until July 2023. Thematic analysis was performed with AtlasTi. Results: The experience that care is not happening quickly enough organizes the trajectory of BC patients under the major, in vivo theme of “Everything is slow.” Managing this wait mobilizes women through clinical milestones, configuring high or low participation scenarios. Scenarios of high participation comprised decisions mostly regarding practical issues, financial and insurance decisions and whatever actions could be taken to shorten waiting times. Scenarios of low‐experienced participation coincided with clinical encounters with health professionals, with treatment decisions delegated to or exclusively made by clinicians. Conclusion: BC is experienced as a distressing diagnosis. Women prioritize decisions that they perceive will speed up their care and do not effectively participate in treatment decision‐making. This study is part of a larger mixed‐methods project that aims to elucidate factors influencing SDM in BC. Future directions should provide strategies to patients and clinicians to build more symmetrical relationships and evaluate the satisfaction with care of universal coverage‐oriented policies, as well as how this could influence the exercise of patients' autonomy.
- 28 March 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (4) , e70138
What Decisions Matter to Women Facing a Breast Cancer Diagnosis? A Case Study From the Global South on Treatment Shared Decision‐Making and the Management of Distress
Background: Breast cancer (BC) is the leading cause of cancer deaths among Chilean women. BC treatment is guaranteed by Chilean law through the Explicit Health Guarantees (GES) plan. There is insufficient evidence on how women navigate the healthcare system and how they exercise shared decision‐making (SDM) following a BC diagnosis in global South scenarios. Aim: To understand how women make decisions about BC treatment. Methods: A qualitative study based on 29 individual, semi‐structured, in‐depth interviews with women undergoing BC treatment in three hospitals in Santiago. Recruitment took place from November 2022 until July 2023. Thematic analysis was performed with AtlasTi. Results: The experience that care is not happening quickly enough organizes the trajectory of BC patients under the major, in vivo theme of “Everything is slow.” Managing this wait mobilizes women through clinical milestones, configuring high or low participation scenarios. Scenarios of high participation comprised decisions mostly regarding practical issues, financial and insurance decisions and whatever actions could be taken to shorten waiting times. Scenarios of low‐experienced participation coincided with clinical encounters with health professionals, with treatment decisions delegated to or exclusively made by clinicians. Conclusion: BC is experienced as a distressing diagnosis. Women prioritize decisions that they perceive will speed up their care and do not effectively participate in treatment decision‐making. This study is part of a larger mixed‐methods project that aims to elucidate factors influencing SDM in BC. Future directions should provide strategies to patients and clinicians to build more symmetrical relationships and evaluate the satisfaction with care of universal coverage‐oriented policies, as well as how this could influence the exercise of patients' autonomy.
- Top Cited PapersOpen Access
- 16 November 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 78, 102942
Global unmet psychosocial needs in cancer care: health policy
- 16 November 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 78, 102942
Top Cited PapersOpen AccessGlobal unmet psychosocial needs in cancer care: health policy
- Open Access
- 1 August 2024
- Published by Pontificia Universidad Catolica de Chile
- Vol. 35 (2) , 595-607
CONSTRUCCIÓN Y VALIDACIÓN GUÍA PARA LAS BUENAS PRÁCTICAS DE COMUNICACIÓN DE RIESGO DURANTE CRISIS SANITARIAS
INTRODUCCIÓN. La pandemia COVID-19 evidenció la necesidad de contar con estrategias de comunicación de riesgo efectivas y contextualizadas al territorio, para la toma de decisión informada de la comunidad. OBJETIVO. describir la construcción y validación por expertos de una Guía de Buenas Prácticas para Comunicación de Riesgo durante una crisis sanitaria (GBP-CR) en el contexto chileno. MATERIAL Y MÉTODOS. Estudio multi método y de validez de constructo para los elementos de evaluación de la guía. RESULTADOS. Se construyó una GBP-CR que aborda contenidos teóricos sobre comunicación de riesgo (CR), institucionalización de la estrategia, su enfoque y análisis del contexto de implementación. Incluye recomendaciones para construir, transmitir y evaluar el mensaje para una CR efectiva y rúbricas para valorar tres aspectos centrales de los comunicados. CONCLUSIÓN. Se construyó la primera Guía de Buenas Prácticas para la Comunicación de Riesgo durante una crisis sanitaria basada en evidencia y ajustada a la realidad local.
- 1 August 2024
- Published by Pontificia Universidad Catolica de Chile
- Vol. 35 (2) , 595-607
Open AccessCONSTRUCCIÓN Y VALIDACIÓN GUÍA PARA LAS BUENAS PRÁCTICAS DE COMUNICACIÓN DE RIESGO DURANTE CRISIS SANITARIAS
INTRODUCCIÓN. La pandemia COVID-19 evidenció la necesidad de contar con estrategias de comunicación de riesgo efectivas y contextualizadas al territorio, para la toma de decisión informada de la comunidad. OBJETIVO. describir la construcción y validación por expertos de una Guía de Buenas Prácticas para Comunicación de Riesgo durante una crisis sanitaria (GBP-CR) en el contexto chileno. MATERIAL Y MÉTODOS. Estudio multi método y de validez de constructo para los elementos de evaluación de la guía. RESULTADOS. Se construyó una GBP-CR que aborda contenidos teóricos sobre comunicación de riesgo (CR), institucionalización de la estrategia, su enfoque y análisis del contexto de implementación. Incluye recomendaciones para construir, transmitir y evaluar el mensaje para una CR efectiva y rúbricas para valorar tres aspectos centrales de los comunicados. CONCLUSIÓN. Se construyó la primera Guía de Buenas Prácticas para la Comunicación de Riesgo durante una crisis sanitaria basada en evidencia y ajustada a la realidad local.
- Open Access
- 18 September 2023
- Published by Springer Nature in Globalization and Health
- Vol. 19 (1) , 1-12
Registering transparency: the making of the international clinical trial registry platform by the world health organization (2004–2006)
Background: This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the sequence of actions following the GSK Paxil scandal in 2004, identifying the major ethical and scientific arguments that led to the involvement of the WHO as a key actor in trial registration in the context of the Big Pharma business model. Results: Through the questions “Why register?” and “Why registries?” as a roadmap, I examine the issues of publication bias and selective reporting by the industry, scrutinizing two ways in which the practice of publication bias damaged transparency in industry-sponsored research. The first involved ethical concerns regarding human subject exploitation and concealing of negative results. The second addresses the deterioration of the certainty of evidence due to incomplete access to trials results. By reviewing the series of events that occurred between 2004 and 2006 –between the Paxil scandal and the launch of the ICTRP—, I analyze the actions taken by the different actors involved: (1) the International Committee of Medical Journal Editors (ICMJE) and the creation of the Ottawa Group; (2) the WHO, beginning with the Ministerial Summit on Health Research held in November of 2004, and (3) the responses of the pharmaceutical industry and specifically GSK to the call for transparency and trial registration. Conclusions: The history of trial registration through the ICTRP as a dataveillance apparatus shows the difficulty of regulating a health enterprise turned into a global business. Moreover, it shows the challenges of globalization and how easier and faster it is to globalize business compared to good practices, raising the question of why it has been so hard to undo these trends. Indeed, the history of the movement for trial registration is not a history of regulation success, or at least not yet.
- 18 September 2023
- Published by Springer Nature in Globalization and Health
- Vol. 19 (1) , 1-12
Open AccessRegistering transparency: the making of the international clinical trial registry platform by the world health organization (2004–2006)
Background: This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the sequence of actions following the GSK Paxil scandal in 2004, identifying the major ethical and scientific arguments that led to the involvement of the WHO as a key actor in trial registration in the context of the Big Pharma business model. Results: Through the questions “Why register?” and “Why registries?” as a roadmap, I examine the issues of publication bias and selective reporting by the industry, scrutinizing two ways in which the practice of publication bias damaged transparency in industry-sponsored research. The first involved ethical concerns regarding human subject exploitation and concealing of negative results. The second addresses the deterioration of the certainty of evidence due to incomplete access to trials results. By reviewing the series of events that occurred between 2004 and 2006 –between the Paxil scandal and the launch of the ICTRP—, I analyze the actions taken by the different actors involved: (1) the International Committee of Medical Journal Editors (ICMJE) and the creation of the Ottawa Group; (2) the WHO, beginning with the Ministerial Summit on Health Research held in November of 2004, and (3) the responses of the pharmaceutical industry and specifically GSK to the call for transparency and trial registration. Conclusions: The history of trial registration through the ICTRP as a dataveillance apparatus shows the difficulty of regulating a health enterprise turned into a global business. Moreover, it shows the challenges of globalization and how easier and faster it is to globalize business compared to good practices, raising the question of why it has been so hard to undo these trends. Indeed, the history of the movement for trial registration is not a history of regulation success, or at least not yet.
- Open Access
Factors influencing the implementation of shared decision-making in breast cancer care: protocol for a mixed-methods study
Introduction Chile is committed to actively involving patients in their healthcare. However, little is known about how this is translated into clinical encounters. Breast cancer (BC) is the first cause of cancer-related death in Chilean women. National policy guarantees standard care, and treatment decisions should be made along this process that can have long-term consequences for women. So, BC is a particularly well-suited case study to understand the complexity of patient participation in decision-making. Objective To identify the factors that affect the active involvement of patients in the BC treatment decision-making process, considering the perspectives and practices of health professionals and women facing the disease. Method and analysis We will conduct a mixed-method study through a convergent parallel design in three stages: (1) A qualitative study: non-participant observation of the tumour board (TB) meetings; semi-structured interviews with key informants from TBs; documentary analyses; semi-structured interviews with women facing BC; and non-participant observations of clinical encounters; (2) a cross-sectional study with 445 women facing BC stages I–III from three hospitals in Santiago, Chile. We will measure the level of expected participation, experienced participation, decisional conflict, quality of life (QoL) and satisfaction with healthcare. Descriptive analysis will be performed, and multivariable binary logistic regression models will be adjusted to identify factors associated with high levels of QoL or satisfaction; (3) an integration study will bring together the data through a joint display technique. Ethics and dissemination The study has been conceived and will be conducted according to international and local agreements for ethical research. Ethical approval has been granted by two Ethics Committees in Chile. The results will be disseminated to scientific and lay audiences (publications in scientific journals and conferences, seminars and a website for plain language dissemination).
Open AccessFactors influencing the implementation of shared decision-making in breast cancer care: protocol for a mixed-methods study
Introduction Chile is committed to actively involving patients in their healthcare. However, little is known about how this is translated into clinical encounters. Breast cancer (BC) is the first cause of cancer-related death in Chilean women. National policy guarantees standard care, and treatment decisions should be made along this process that can have long-term consequences for women. So, BC is a particularly well-suited case study to understand the complexity of patient participation in decision-making. Objective To identify the factors that affect the active involvement of patients in the BC treatment decision-making process, considering the perspectives and practices of health professionals and women facing the disease. Method and analysis We will conduct a mixed-method study through a convergent parallel design in three stages: (1) A qualitative study: non-participant observation of the tumour board (TB) meetings; semi-structured interviews with key informants from TBs; documentary analyses; semi-structured interviews with women facing BC; and non-participant observations of clinical encounters; (2) a cross-sectional study with 445 women facing BC stages I–III from three hospitals in Santiago, Chile. We will measure the level of expected participation, experienced participation, decisional conflict, quality of life (QoL) and satisfaction with healthcare. Descriptive analysis will be performed, and multivariable binary logistic regression models will be adjusted to identify factors associated with high levels of QoL or satisfaction; (3) an integration study will bring together the data through a joint display technique. Ethics and dissemination The study has been conceived and will be conducted according to international and local agreements for ethical research. Ethical approval has been granted by two Ethics Committees in Chile. The results will be disseminated to scientific and lay audiences (publications in scientific journals and conferences, seminars and a website for plain language dissemination).
- Open Access
What is needed to effectively communicate risk during a health crisis? A qualitative study with international experts based on the COVID-19 pandemic
Objective To identify a framework for risk communication during health crises by using the current pandemic as a case study. Design A qualitative study based on individual interviews. Setting Different countries with diverse levels of perceived success on risk communication during the COVID-19 health crisis. Participants International experts with experience in health crisis management or risk communication. Analysis A thematic analysis was performed supported by Atlas.ti. Results Four men and six women took part in the study (three from Europe, two from Latin America, two from North America, one from Asia and two from Oceania). Three major themes emerged from the data: (1) institutionalising the communication strategy; (2) defining the problem that needs to be faced; (3) developing an effective communication strategy. Conclusion Risk communication during a health crisis requires preparation of governments and of health teams in order to produce and deliver effective messages as well as to help communities to make informed and healthy decisions. This is particularly relevant for slow disasters, such as COVID-19, as the strategy must innovate to avoid information fatigue of the audience. The findings of this article could inform guidelines to best equip countries for a clear communication strategy for future crises. PROSPERO registration number CRD42021234443.
Open AccessWhat is needed to effectively communicate risk during a health crisis? A qualitative study with international experts based on the COVID-19 pandemic
Objective To identify a framework for risk communication during health crises by using the current pandemic as a case study. Design A qualitative study based on individual interviews. Setting Different countries with diverse levels of perceived success on risk communication during the COVID-19 health crisis. Participants International experts with experience in health crisis management or risk communication. Analysis A thematic analysis was performed supported by Atlas.ti. Results Four men and six women took part in the study (three from Europe, two from Latin America, two from North America, one from Asia and two from Oceania). Three major themes emerged from the data: (1) institutionalising the communication strategy; (2) defining the problem that needs to be faced; (3) developing an effective communication strategy. Conclusion Risk communication during a health crisis requires preparation of governments and of health teams in order to produce and deliver effective messages as well as to help communities to make informed and healthy decisions. This is particularly relevant for slow disasters, such as COVID-19, as the strategy must innovate to avoid information fatigue of the audience. The findings of this article could inform guidelines to best equip countries for a clear communication strategy for future crises. PROSPERO registration number CRD42021234443.
- Open Access
- 16 July 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 31 (3) , 841-853
Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale
Purpose: The aim of this study was to explore what methods should be used to determine the minimal important difference (MID) and minimal important change (MIC) in scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43. Methods: In an international multi-centre study, patients with head and neck cancer completed the EORTC QLQ-HN43 before the onset of treatment (t1), three months after baseline (t2), and six months after baseline (t3). The methods explored for determining the MID were: (1) group comparisons based on performance status; (2) 0.5 and 0.3 standard deviation and standard error of the mean. The methods examined for the MIC were patients' subjective change ratings and receiver-operating characteristics (ROC) curves, predictive modelling, standard deviation, and standard error of the mean. The EORTC QLQ-HN43 Swallowing scale was used to investigate these methods. Results: From 28 hospitals in 18 countries, 503 patients participated. Correlations with the performance status were |r|< 0.4 in 17 out of 19 scales; hence, performance status was regarded as an unsuitable anchor. The ROC approach yielded an implausible MIC and was also discarded. The remaining approaches worked well and delivered MID values ranging from 10 to 14; the MIC for deterioration ranged from 8 to 16 and the MIC for improvement from − 3 to − 14. Conclusions: For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem to be inappropriate.
- 16 July 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 31 (3) , 841-853
Open AccessMethodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale
Purpose: The aim of this study was to explore what methods should be used to determine the minimal important difference (MID) and minimal important change (MIC) in scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43. Methods: In an international multi-centre study, patients with head and neck cancer completed the EORTC QLQ-HN43 before the onset of treatment (t1), three months after baseline (t2), and six months after baseline (t3). The methods explored for determining the MID were: (1) group comparisons based on performance status; (2) 0.5 and 0.3 standard deviation and standard error of the mean. The methods examined for the MIC were patients' subjective change ratings and receiver-operating characteristics (ROC) curves, predictive modelling, standard deviation, and standard error of the mean. The EORTC QLQ-HN43 Swallowing scale was used to investigate these methods. Results: From 28 hospitals in 18 countries, 503 patients participated. Correlations with the performance status were |r|< 0.4 in 17 out of 19 scales; hence, performance status was regarded as an unsuitable anchor. The ROC approach yielded an implausible MIC and was also discarded. The remaining approaches worked well and delivered MID values ranging from 10 to 14; the MIC for deterioration ranged from 8 to 16 and the MIC for improvement from − 3 to − 14. Conclusions: For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem to be inappropriate.